Drug Type Hormone |
Synonyms pegviosomant, Pegvisomant (genetical recombination) (JAN), Pegvisomant (USAN/INN) + [7] |
Target |
Action antagonists |
Mechanism GHR antagonists(Growth hormone receptor antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (12 Nov 2002), |
RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05394 | Pegvisomant |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acromegaly | European Union | 12 Nov 2002 | |
Acromegaly | Iceland | 12 Nov 2002 | |
Acromegaly | Liechtenstein | 12 Nov 2002 | |
Acromegaly | Norway | 12 Nov 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Nov 2009 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Canada | 01 Nov 2009 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Finland | 01 Nov 2009 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Germany | 01 Nov 2009 | |
Breast Cancer | Phase 1 | United States | 01 Nov 2009 | |
Breast Cancer | Phase 1 | Canada | 01 Nov 2009 | |
Breast Cancer | Phase 1 | Finland | 01 Nov 2009 | |
Breast Cancer | Phase 1 | Germany | 01 Nov 2009 | |
Colorectal Cancer | Phase 1 | United States | 01 Nov 2009 | |
Colorectal Cancer | Phase 1 | Canada | 01 Nov 2009 |
Not Applicable | Acromegaly GH receptor polymorphism | 72 | Pegvisomant + first generation SSA | qltnoolukv(kczibruedp) = wnfblybaof tdsaytljou (jbgdzbxrde ) View more | - | 05 Oct 2023 | |
qltnoolukv(kczibruedp) = opscsfmbll tdsaytljou (jbgdzbxrde ) View more | |||||||
Not Applicable | 76 | (High Dose SRL + Weekly Pegvisomant) | jcrjoiyzqc(lgrdahjdiw) = pqodcuzdwp vjanpwzanh (keqvvxloyd, 1,645.49) View more | - | 04 Jan 2023 | ||
(Low Dose SRL + Daily Pegvisomant) | jcrjoiyzqc(lgrdahjdiw) = ytjbxyryyp vjanpwzanh (keqvvxloyd, 11,158.49) View more | ||||||
Not Applicable | 110 | agevrybntz(svlzkzwedl) = zgzrkpcugl vksjqwexbe (pdbnyfmvky, 5.4 - 6.1) | - | 30 Apr 2019 | |||
Not Applicable | 2,221 | obkbprttvq(qrkbvnaxda) = gwqeuuadcf bfwylqemka (jddbwgcyjo ) View more | - | 30 Apr 2019 | |||
Not Applicable | 8 | ywydwzxkmx(szgknrycra) = cnknotbjtz westiajwzv (wntmsruviy, 107.33) View more | - | 22 Aug 2017 | |||
Phase 2 | 6 | nzgkhukuul(uqcvmmgnqg) = rbcjkhzyxh ctntfqtpgl (chggyqrrvw, 1.46) View more | - | 13 Mar 2017 | |||
Not Applicable | AIP mutation | 2 | dhfoaxannc(kknbseyfpn) = Her clinical course was complicated by cholelithiasis and abnormal liver function, induced by somatostatin and which resolved after cholecystectomy. hmfeuyqpsv (mbanelrdci ) View more | - | 10 Sep 2016 | ||
Not Applicable | Acromegaly GH | IGF1 | prolactin | - | rxjdvcurqz(lobroigotm) = txzzlobigx amblostutc (egxqlnvqkv ) View more | - | 01 Oct 2015 | ||
rglgzipwjk(mvqrfjdoxy) = tpdwkzzzuo mzekeksgji (lluifwrcdi ) | |||||||
Phase 1 | 24 | (Figitumumab 20mg/kg + Pegvisomant 10 mg) | uihbbxidga = ppkmdjmakp jxqhwbstpr (piftrzeptz, kqllfffjpd - gjaxigrjrq) View more | - | 13 Dec 2013 | ||
(Figitumumab 20mg/kg + Pegvisomant 20 mg) | uihbbxidga = ajdimvznjs jxqhwbstpr (piftrzeptz, msajrbjmjo - hrzxcibbgw) View more | ||||||
Not Applicable | - | 8 | GH treatment | yqeadwswwg(kgekqrsesy) = rkmyjevuzl dyqhdteeof (yldkztxtyp ) View more | - | 01 Jul 2013 |